慢性乙型重症肝炎及肝癌与血清可溶性Fas/可溶性Fas配体的关系

Ralationship between serum soluble Fas/soluble Fas ligand and chronic serious hepatitis B/hepotocellular carcinoma

目的 探讨血清可溶性Fas/可溶性Fas配体 (sFas/sFasL)水平与慢性乙型重症肝炎以及乙肝病毒相关性肝细胞癌变之间的关系。方法 用酶联免疫吸附双抗体夹心法检测 2 1例无症状乙肝病毒携带者、2 0例慢性乙型重症肝炎及 2 2例乙肝病毒相关性肝细胞癌患者血清sFas、sFasL水平。结果 与无症状乙肝病毒携带者比较 ,慢性乙型重症肝炎患者血清sFas、sFasL水平均增高 ,其差异有显著意义 (P <0 .0 1) ;乙肝病毒相关性肝细胞癌患者sFas水平明显增高 ,而sFasL水平则降低 ,其差异有显著意义。结论 血清sFas、sFasL水平与慢性乙型重症肝炎、乙肝病毒相关性肝细胞癌的发生密切相关。

Objective To study the relationship between soluble Fas/soluble Fas Ligand levels in serum and chronic serious hepatitis B/ hepotocellular carcinoma.Methods Soluble Fas (sFas) and soluble Fas Ligand (sFasL) levels in serum were measured in 21 patients with asymptomatic HBsAg carriers ,20 patients with chronic serious hepatitis B, and 22 patients with hepotocellular carcinoma by enzyme Linked immunosorbent assay (ELISA).Results Compared with asymptomatic HBsAg carriers, the sFas and sFasL levels in serum of patients with chronic serious hepatitis B were both significantly increased ( P <0.01) the sFas level was significantly increased, whereas the sFasL level being decreased.Conclusion There was significant relationship between sFas/sFasL levels and chronic serious hepatitis B/hepotocellular carcinoma.